biotech · Unresectable or metastatic conventional chondrosarcoma · Advanced or metastatic solid tumors · INBX
Inhibrx Biosciences
Inhibrx Biosciences is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker INBX. Primary therapeutic focus areas include Unresectable or metastatic conventional chondrosarcoma, Advanced
San Diego, USA HQ
2010 Founded
114 Employees
Public company Type
INBX · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2010
- Employees
- 114
- Programs
- 10
- Drugs
- 17
- Patents
- 35
INBRX-101/rhAAT-Fc
Phase 1 · small molecule · Alpha-1 Antitrypsin Deficiency
INBRX-101/rhAAT-Fc for Alpha-1 Antitrypsin Deficiency is a Phase 1 program (small_molecule) at Inhibrx Biosciences with 1 ClinicalTrials.gov record(s).
Internal code Ph1 INBRX-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Inhibrx Biosciences
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Alpha-1 Antitrypsin Deficiency
- Status
- completed
- Trials
- 1